(Q36627196)

English

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

scientific article published on 8 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial (English)

1 reference

Europe PubMed Central

15 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Francesco Grossi

object named as

F Grossi

10

0 references

Christos Chouaid

7

object named as

C Chouaid

1 reference

Europe PubMed Central

15 August 2017

0 references

author name string

M Schuler

1

1 reference

Europe PubMed Central

15 August 2017

J C-H Yang

2

1 reference

Europe PubMed Central

15 August 2017

K Park

3

1 reference

Europe PubMed Central

15 August 2017

J-H Kim

4

1 reference

Europe PubMed Central

15 August 2017

J Bennouna

5

1 reference

Europe PubMed Central

15 August 2017

Y-M Chen

6

1 reference

Europe PubMed Central

15 August 2017

F De Marinis

8

1 reference

Europe PubMed Central

15 August 2017

J-F Feng

9

1 reference

Europe PubMed Central

15 August 2017

D-W Kim

11

1 reference

Europe PubMed Central

15 August 2017

X Liu

12

1 reference

Europe PubMed Central

15 August 2017

S Lu

13

1 reference

Europe PubMed Central

15 August 2017

J Strausz

14

1 reference

Europe PubMed Central

15 August 2017

Y Vinnyk

15

1 reference

Europe PubMed Central

15 August 2017

R Wiewrodt

16

1 reference

Europe PubMed Central

15 August 2017

C Zhou

17

1 reference

Europe PubMed Central

15 August 2017

B Wang

18

1 reference

Europe PubMed Central

15 August 2017

V K Chand

19

1 reference

Europe PubMed Central

15 August 2017

D Planchard

20

1 reference

Europe PubMed Central

15 August 2017

LUX-Lung 5 Investigators

21

1 reference

Europe PubMed Central

15 August 2017

publication date

8 December 2015

1 reference

Europe PubMed Central

15 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

15 August 2017

27

1 reference

Europe PubMed Central

15 August 2017

417-423

1 reference

Europe PubMed Central

15 August 2017

3

1 reference

Europe PubMed Central

15 August 2017

Rociletinib in EGFR-mutated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

30 September 2017

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

28 June 2018

Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

20 September 2018

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4769992

20 September 2018

Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26646759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDV597

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36627196&oldid=1641668698"